Its roles Owner Operator
Eli Lilly and Company (Lilly; NYSE: LLY) is a U.S.-based global pharmaceutical manufacturer that discovers, develops, and produces medicines for human health. Founded in 1876 and headquartered in Indianapolis, Indiana, the company’s portfolio spans small‑molecule and biologic therapies, with core focus areas including diabetes and metabolic diseases, immunology, oncology, and neuroscience.
Across the chemicals and life‑sciences value chain, Lilly operates extensive R&D and manufacturing networks for active pharmaceutical ingredients (APIs), biologics, and sterile injectable formulations, supported by global quality, regulatory, and supply‑chain systems. The company also develops drug‑delivery devices and collaborates with academic and industry partners to advance new therapeutic modalities.
Also known as Eli Lilly, Lilly USA, LLY, Eli Lilly USA, LLC, and Eli Lilly and Company.
chemXplore tracks 11 projects involving Lilly, of which 8 are active.
Besides these 8, the record holds 3 completed projects.
Closest to start-up first.
2 more active projects and the 3 that are completed, on hold or cancelled are in the record. See all 11 in chemXplore →
1 active project carries no start-up date yet. The dates themselves, per project, are for subscribers.
At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.
Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.
Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.
$5 billion Richmond facility will produce antibody-drug conjugates with integrated API and finished-medicine capacity, add 650 high-wage roles, and fund training with a $40 million commitment.
Patients reached composite corticosteroid‑free endpoints at one year in ulcerative colitis and Crohn's disease, including people with prior biologic failure; composite outcomes correlated with better IBDQ scores.
Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
FDA clears pirtobrutinib for newly diagnosed CLL/SLL patients without 17p deletion after BRUIN CLL-313 showed a large PFS benefit versus bendamustine–rituximab.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
